• Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

  NCT00428844

  CompletedInterventionalPhase 2Updated Jan 31, 2018
• Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

  NCT01196169

  TerminatedInterventionalPhase 4Updated Feb 3, 2014
• Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial

  NCT06189885

  Unknown statusInterventionalNot ApplicableUpdated Jan 5, 2024
• Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

  NCT00463801

  TerminatedInterventionalPhase 4Updated Mar 24, 2011
• Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia

  NCT02972983

  CompletedInterventionalPhase 4Updated Sep 22, 2020
• Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection

  NCT06172010

  RecruitingInterventionalPhase 4Updated Dec 15, 2023

ClinicalTrials.gov ID

NCT01144000

Lead Sponsor

Andrej TrampuzOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2

Enrollment

60Estimated

Last Update Posted

Jun 26, 2012Estimated

Start Date

Jun 2012

Primary Completion Date

Jun 2014Estimated

Completion Date

Jun 2016Estimated

Official Title

Efficacy and Safety of Daptomycin (With or Without Rifampin) in the Treatment of Staphylococcal Hip, Knee and Shoulder Prosthetic Joint Infection

Brief Summary

To determine the outcome and safety of a combined antimicrobial treatment involving daptomycin and surgical approach involving retention or short-interval two-stage exchange of the implant. Patients with hip, knee and shoulder Prosthetic Joint Infection (PJI) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included and followed during 2 years.

Detailed Description

In this prospective open observational clinical study (phase 2) patients with hip, knee and shoulder PJI (as defined below) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included. An informed consent will be obtained prior to patient inclusion. Medical records will be prospectively abstracted for demographic characteristics, clinical, radiographic, laboratory and microbiologic data using a standardized case report form (CRF). After inclusion, intravenous daptomycin 10 mg/kg (calculated as actual body weight) is given once daily for 2-3 weeks, followed by oral rifampin-containing antibiotics for a total of 3 months (as outlined below).

Two surgical modalities will be applied according to the PJI treatment algorithm:

• Open debridement and retention of the prosthesis (change of mobile parts): daptomycin will be combined with rifampin.
• Two-stage exchange of the prosthesis with a short interval (2-3 weeks): daptomycin of the prosthesis: daptomycin will be used alone.

The decision whether the implant will be retained or removed is based on objective criteria of the treatment algorithm and is not subject to bias. All consecutive patients with a staphylococcal PJI infection of the hip, knee or shoulder prosthesis will be included, if no exclusion criterion is present, obviating the selection bias. Since not many specialized institutions are treating patients with PJI, we expect low number of patients.

• Staphylococcal Infections

• Daptomycin

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Informed consent has been obtained;
2. Subject is 18-80 years of age;
3. Subject has a PJI of the hip, knee and shoulder prosthesis caused by Staphylococcus aureus or coagulase-negative staphylococci (CNS) susceptible to daptomycin and rifampin;
4. Surgical approach: Debridement and retention of the prosthesis OR a two-stage prosthesis exchange with a short interval (2-3 weeks). The selection of the surgical procedure is performed according to the PJI treatment algorithm;
5. Subject is willing to participate in the study, to follow protocol study treatment regimen, and to comply with all planned follow-up assessments;
6. Females of childbearing potential are willing to practice reliable birth control measures other than oral contraceptives (e.g., condoms or diaphragms together with a spermicidal foam or gel) and willing to undergo a urine pregnancy test prior to study entry.

Exclusion Criteria:

1. Significant renal insufficiency (creatinine clearance rate ≤30 ml/min, as determined by the Cockcroft-Gault equation at inclusion);
2. Significant hepatic dysfunction at inclusion (AST or ALT ≥4 x upper limit of normal value);
3. Elevated creatin phosphokinase (CPK) ≥2 x upper limit of normal value at inclusion
4. PJI caused by additional microorganism;
5. Non-adherence to the PJI treatment algorithm (see below);
6. Subject has been previously enrolled in the study or is currently enrolled in another investigational study previously enrolled in the study or is currently enrolled in another investigational study, which deviates from the treatment algorithm;
7. Subject had prior exposure to daptomycin within the past 3 months;
8. Allergy or intolerance to daptomycin or rifampin, known hypersensitivity;
9. Body mass index (BMI) >45 kg/m²;
10. Subject is pregnant, nursing or lactating;
11. Inability to read and understand the participant's information.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Andrej TrampuzOTHER

Collaborators

University of Lausanne HospitalsOTHER

Kantonsspital LiestalOTHER

Schulthess KlinikOTHER

werner.zimmerli@ksli.ch+41 61 925 1111

markus.vogt@zgks.ch